2 Information about roxadustat
Marketing authorisation indication
2.1 Roxadustat (Evrenzo, Astellas Pharma) 'is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for roxadustat.
Price
2.3 The list prices of roxadustat are:
-
£59.24 per 12‑tablet pack, each tablet contains 20 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)
-
£148.11 per 12‑tablet pack, each tablet contains 50 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)
-
£207.35 per 12‑tablet pack, each tablet contains 70 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)
-
£296.21 per 12‑tablet pack, each tablet contains 100 mg of roxadustat (excluding VAT; BNF online, accessed December 2021)
-
£444.32 per 12‑tablet pack, each tablet contains 150 mg of roxadustat (excluding VAT; BNF online, accessed December 2021).
The company has a commercial arrangement. This makes roxadustat available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.